J Cancer 2019; 10(15):3472-3480. doi:10.7150/jca.29672

Research Paper

Immunopotentiator Aikejia improves the therapeutic efficacy of PD-1/PD-L1 immunosuppressive pathway in CT26.WT cancer cell

Chaoqun Huang1,2, Xiaoqiong Tang1, Suhuan Li1, Qingshui Wang1, Bifeng Xie1, Jing Xu3, Yao Lin1 ✉

1. Key Laboratory of Optoelectronic Science and Technology for Medicine of Ministry of Education, College of Life Sciences, Fujian Normal University, Fuzhou 350117, Fujian Province, People's Republic of China.
2. Central laboratory, The Fifth Hospital of Xiamen, Xiamen 361101, Fujian Province, People's Republic of China.
3. Shanhe Pharmaceutical Co., Ltd., No789, Hangang West Road, Chigang Overseas Chinese Economic Development Zone, Putian 351100, Fujian Province, People's Republic of China.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Huang C, Tang X, Li S, Wang Q, Xie B, Xu J, Lin Y. Immunopotentiator Aikejia improves the therapeutic efficacy of PD-1/PD-L1 immunosuppressive pathway in CT26.WT cancer cell. J Cancer 2019; 10(15):3472-3480. doi:10.7150/jca.29672. Available from http://www.jcancer.org/v10p3472.htm

File import instruction

Abstract

Tumors can escape immunosurveillance through immunocheckpoint such as the PD-1/PD-L1 pathway. Aikejia comes from Nocardia rubra cell-wall skeleton and can increase the number of inflammatory factors and immune cells. In this work, we showed that the levels of PD-L1 increase in CT26.WT xenograft after subcutaneous injection of Aikejia in mice, but Aikejia did not induce the expression of PD-L1 in vitro. When we treated the mice with Aikejia and blocked PD-1/PD-L1 pathway in vivo at the same time, the CT26.WT xenografts were significantly inhibited or eliminated, which was better than single treatment alone. Our results suggested that Aikejia may be an effective adjuvant for PD-1/PD-L1 immunotherapy.

Keywords: PD-L1, Aikejia, immunotherapy